Fate Therapeutics, Inc. (FATE) P/S ratio

P/S ratio today
18.2×

Fate Therapeutics, Inc. (FATE) trades at 18.2× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 17.5×. That is 27.3% higher than the 13.8× of fiscal 2024. Figures as of 18 Nov 2026, 03:13 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
18.2×
P/S ratio, fiscal 2025
17.5×
Change on fiscal 2024
+27.3%
Highest on record
238.3×fiscal 2020
Lowest on record
5.8×fiscal 2023
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Fate Therapeutics, Inc. P/S ratio, in more detail

Today's figure is 4.1% above the fiscal 2025 year-end.

Across the 6 fiscal year-ends on record (2020–2025), the highest was 238.3× in fiscal 2020 and the lowest 5.8× in fiscal 2023. Today's P/S ratio is higher than at 67% of the 6 fiscal year-ends on record; their median is 15.6×.

History · 6 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Fate Therapeutics, Inc. P/S ratio, year by year

Fate Therapeutics, Inc. (FATE) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today18.2×—$1.02—
202517.5× 27.3% up$0.98$0.06
202413.8× 137.5% up$1.65$0.12
20235.8× 42.9% down$3.74$0.65
202210.1× 89.8% down$10.09$0.99
202199.3× 58.3% down$58.51$0.59
2020238.3×—$90.93$0.38
2019——$19.57—
2018——$12.83—
2017——$6.11—
2016——$2.51—
2015——$3.37—
2014——$5.03—
2013——$6.28—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on FATE

Fate Therapeutics, Inc., figure by figure

Fate Therapeutics, Inc. (FATE) overview: price, valuation and scorecard

Fate Therapeutics, Inc. P/S ratio: questions and answers

What is Fate Therapeutics, Inc.'s P/S ratio?

Fate Therapeutics, Inc. (FATE) trades at 18.2× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 17.5×. That is 27.3% higher than the 13.8× of fiscal 2024.

Is Fate Therapeutics, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 67% of the 6 fiscal year-ends on record; their median is 15.6×.

What are the highest and lowest P/S ratio figures on record for Fate Therapeutics, Inc.?

Across the 6 fiscal year-ends on record (2020–2025), the highest was 238.3× in fiscal 2020 and the lowest 5.8× in fiscal 2023.

How is Fate Therapeutics, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Fate Therapeutics, Inc. (FATE) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/FATE/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.